sequent chemotherapy and/or radiotherapy are the traditional treatments for this cancer, but the use of chemotherapeutic drugs often is limited since these drugs are not specific to cancer cells but give severe toxic effects on normal proliferative cells such as intestinal gland cells.
Over the last decades, new therapeutic regimens for CRC treatment such as molecular targeted therapy have been employed. However, as seen in almost all other cancers, drug resistance and serious side effects of drugs also occur, which result in the relapse of tumor and cessation of drug administration respectively (Britten, 2013) . Thus, it is of clinical significance in the area of oncology to develop new therapeutic strategy to overcome drug resistance and reduce the incidents of side effects.
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways play key roles in controlling cell survival, proliferation, differentiation and motility in response to various growth factors (Mendoza et al., 2011) . Aberrant regulation induced by gene mutation or amplification in the components of these signaling pathways is implicated in malignant transformation, tumorigenesis and drug resistance (McCubrey et al., 2007) . Thus, much effort has been made to develop molecular inhibitors targeting these pathways (De Luca et al., 2012) . During the last decade, simultaneous treatment with two pathway inhibitors has been suggested for more effective therapeutic intervention, since cross-talk and pathway convergence between these two pathways have been described and cancer cells with RAS mutation is capable of signaling through both pathways (Mendoza et al., 2011) . However, the combined targeting strategy often proved to cause significant unacceptable drug-related toxicity, resulting in termination of clinical trials (Britten, 2013 ).
Metformin, a biguanide derivative, has been widely prescribed for treatment of type 2 diabetes mellitus for over 50 years and proved a well-tolerable drug with low cost. Several retrospective and case-control studies indicated that type 2 diabetes mellitus is associated with high risk for certain types of cancer including CRC (Larsson et al., 2005; MacKenzie et al., 2011) , and metformin treatment in diabetic patients significantly reduced the risk of CRC compared with the control group (Tseng, 2012 ). Metformin usage in CRC patients with diabetic mellitus showed a 40% improvement in overall survival when compared with patients treated with the other antidiabetic agents (Garrett et al., 2012) . In accordance with these studies of reduced cancer risk, metformin is activating AMP-activated protein kinase (AMPK) which is a central master of cellular energy metabolism, cell survival and proliferation (Griss et al., 2015) . In preclinical studies, metformin exerts anti-proliferative effect in diverse cancer cells including CRC cells and inhibits tumor growth in vivo xenograft studies (Buzzai et al., 2007; Nangia-Makker et al., 2014) . Moreover, many researchers showed that combined treatment of metformin with other chemotherapeutic and targeted agents synergistically increases the anticancer effect, suggesting the possibility to reduce the dose of drugs with severe toxicity (Iliopoulos et al., 2011; Zhang & Guo, 2016) .
In our previous studies using HCT15 CRC cells with coexistent mutations of KRAS and PIK3CA, we showed that metformin treatment decreases the level of pERK, one of the key regulatory components in RAS/RAF/MEK/ERK signaling pathway, and dual PI3K/mTOR inhibitor BEZ235 induces the inhibition of cell proliferation (Oh et al., 2016; Lee et al., 2017) . Therefore, we hypothesized that the combination of metformin with BEZ235 could not only potentiate the anti-tumor activity as compared to single agent treatment, but also reduce serious side effects resulting from the combinational regimen which co-targets the two signaling pathways by using other inhibitors with severe toxicity. In the present study, we investigated 1) whether the combination of metformin with BEZ235 could lead to dual pathway inhibition, 2) whether the combination treatment regime would be more effective than either agent alone in inhibiting cell proliferation, and 3) whether the combination would change the pattern of cell cycle distribution in HCT15 CRC cells.
Reagents and cell culture
The human colorectal cancer cell line HCT15 was pur- 
Cell viability assay
MTT assay was applied to measure cell viability as described previously (Lee et al., 2017) . Briefly, cells were 
Western blotting
Western blotting assays were carried out as previously described (Oh et al., 2016) . Primary antibodies included pERK1/2 (Tyr204), ERK1/2, cyclin D1, cyclin B1 (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and pRb (Ser807/811), p27 Kip1, p4E-BP1 (Ser65), 4E-BP1, pS6 (Ser240/244), S6 (all from Cell Signaling Technology, MA, USA). Following incubation with secondary antibodies conjugated to horseradish peroxidase (Cell Signaling), immunoreactivity was detected with enhanced chemiluminescence method (Santa Cruz Biotechnology).
Cell cycle analysis
Flow cytometry to determine cell cycle distribution was performed as previously described (Lee et al., 2017) . 
Colony formation assay
Cells were plated in 6-well culture dishes at a density of We also found that the DRI values were always above 1 at any combination of two drugs (Fig. 2C) . min, and the effect was further enforced by the combination of BEZ235 and metformin (Fig. 4) .
Metformin potentiates the inhibitory effect of BEZ235 on the colony formation
We investigated whether metformin augments the antiproliferative activity of BEZ235 in the long term culture system using colony formation assay. As shown in Fig. 5,   BEZ235 or metformin alone at the tested doses in a 12-day culture resulted in a partial inhibition of colony formation.
On the other hand, the combined treatment with BEZ235
and metformin potentiated the inhibitory effect on the formation and growth of colonies when compared with either agent alone. Thus, these results further support the synergistic anti-proliferative effect of BEZ235 and metformin in Cell survival and proliferation are mainly dependent on the regulation of RAS/RAF/MEK/ERK and PI3K/AKT/ mTOR cell signaling pathways, and alteration of downstream components of these signaling cascades, either through somatic mutation or epigenetic modification is often implicated in tumorigenesis (Liu et al., 2009; Santarpia et al., 2012) . Although drugs targeting these pathways, developed and approved for treatment of cancer patients, showed remarkable responses in certain cancer types, many challenging issues such as drug resistance and side effects remain unresolved. Mechanistic studdies revealed the drug resistance is related to a negative crosstalk between two signaling pathways (Mendoza et al., 2011) . Several preclinical studies using various cancer cells demonstrated that combined targeting of these two pathways is more effective in suppression of cancer cell proliferation compared to the single treatment groups (Britten, 2013; Posch et al., 2013) . However, clinical trials of this co-targeting strategy achieved tumor regression to varied extent between 25 and 64%, and the combination therapy caused severe drug-related toxicity in colorectal cancer patients (Shimizu et al., 2012) .
In this study, we showed that metformin combined with BEZ235 is able to synergistically increase the anti-tumor activity in HCT15 CRC cells harboring both KRAS and PIK3CA mutations. CRC patients with KRAS mutations showed poorer overall survival and increased risk of relapse, especially when the conventional first-line chemotherapies have failed (Andreyeb et al., 1998) . Moreover, targeted therapies against the epidermal growth factor receptor (EGFR) using cetuximab and panitumumab provide no benefit to CRC patients with KRAS mutations, although anti-EGFR treatment improves the response rate and overall survival in patients with KRAS-wild type CRC (Lievre et al., 2006; Benvenuti et al., 2007; Amado et al., 2008; Gong et al., 2016 (Bennouna et al., 2011; Gong et al., 2016) . Our previous studies using HCT15 CRC cell showed that metformin suppresses the phosphorylation of ERK and induces cell cycle arrest in S phase (Lee et al., 2017) , and BEZ235, a dual inhibitor of PI3k and mTOR, produces G1 cell cycle arrest (Oh et al., 2016) . Therefore, we reasoned that a combination of metformin and BEZ235 could provide Quinn et al., 2013) . Here, our present result showed that metformin reduces the phosphorylation of ERK1/2 as well as S6 and 4E-BP1. We considered that metformin might increase the phosphorylation of ERK1/2 since these two pathways has been known to negatively regulate each other's activity via cross-inhibition (Mendoza et al., 2011) . At present, we have no idea on this contradictory outcome. However, there are several studies showing the reduction of pERK in response to metformin (Niehr et al., 2011; Mohammed et al., 2013) . Metformin leads to a dramatic reduction in epidermal growth factor activation and other receptor tyrosine kinases such as human epidermal growth receptor 2, which can inhibit the signaling through downstream pathways including the phosphorylation of ERK (Memmott et al., 2010; Ma et al., 2014) . Metformin also suppressed tumor cell migration and invasion through inhibiting the phodphorylation of ERK (Hsieh et al., 2014) . Of note, Niehr et al. (2011) and our unpublished in vitro studies showed that synergy obtained from combination of metformin with other targeted drugs is associated with reduction of pERK following metformin treatment.
Thus, we tentatively suggest that the suppression of pERK in response to metformin could serve as a biomarker to predict potential synergism in the anticancer therapeutics using drug combination with metformin.
Taken together, our study provides evidence that the combination of an inhibitor of PI3K/AKT/mTOR pathway with metformin synergistically induces anticancer effects in HCT15 colorectal cancer cells with mutations of both KRAS and PIK3CA via suppression of pERK. Additional studies are needed to delineate the in vivo effect of our combination strategy, but our study suggests a possible therapeutic option for treatment of colorectal cancer, especially harboring KRAS mutation.
